Drug intelligence / Profile preview

thiopenafigrastine

Development stage: Preclinical
Lead developer: Abbott
Administration: Intravenous, Rectal, Oral

Overview

Thiopenafigrastine is a drug being investigated for its safety and effectiveness in preventing moderate to severe chemotherapy-related neutropenia in breast cancer patients. Details regarding its specific mechanism of action, developer, or manufacturer are not publicly available from the provided context or search results.

Targets

GABRR (GABA-A receptor subunit rho)Nicotinic Acetylcholine ReceptorHTR3A (5-hydroxytryptamine receptor 3A)Glycine receptor

Beyond the preview

Go deeper on thiopenafigrastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thiopenafigrastine.

Explore the full profile